Immunic, Inc., a late-stage biotechnology company, recently executed a 1-for-10 reverse stock split to satisfy obligations under a securities purchase agreement and regain Nasdaq listing compliance. While this move reduces the number of outstanding shares, it may also signal the potential for future equity financing and corresponding shareholder dilution. Current indicators show a moderate risk profile and warrant continued monitoring.
